文献速递血液净化与透析

老年血透患者动静脉通路类型与死亡、住院及脓毒症风险:目标试验模拟

Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach.
PubMed 文献 · Am J Kidney Dis · 2021-06-09

本研究采用目标试验模拟法,在19,867例以导管起始血透并6个月内建立动静脉通路的老年患者中比较动静脉内瘘(AVF)与动静脉移植物(AVG)。倾向评分加权显示AVF与6个月内死亡和全因住院风险较低相关(HR分别为0.82),但工具变量分析未发现AVF与死亡、脓毒症或全因、心血管病相关、感染相关住院相关。

要点

  • 倾向评分加权分析中,AVF与6个月内死亡和全因住院风险较低相关(HR均为0.82)
  • 工具变量分析未发现AVF与死亡、脓毒症或全因、心血管病相关、感染相关住院相关
  • AVF与感染无关的通路相关住院风险较低相关

核心结论

  • 在老年以导管起始血透患者中,初始动静脉通路类型与死亡、脓毒症或全因、心血管病相关、感染相关住院风险无关。

研究设计与样本

  • 回顾性队列研究,采用目标试验模拟法,纳入US Renal Data System中19,867例以导管起始血透并6个月内建立AVF或AVG的老年患者。

主要发现

  • 未加权分析中,AVF与死亡和住院风险显著较低相关,尤其在通路建立后6个月内。
  • 倾向评分加权分析中,AVF与6个月内死亡风险较低相关(HR 0.82,95%CI 0.75-0.91)和全因住院风险较低相关(HR 0.82,95%CI 0.78-0.87),但6个月至3年间无关联。
  • 工具变量分析中,AVF与死亡、脓毒症或全因、心血管病相关、感染相关住院均无关联。
  • 工具变量分析中,AVF与感染无关的通路相关住院风险较低相关。

临床怎么用

  • 老年以导管起始血透患者选择AVF或AVG时,应综合考虑,不能仅依据死亡或感染住院风险做决策。

局限性

  • 可能存在未测量混杂。
  • 分析仅限老年患者。
  • 缺乏随访期间通路实际使用数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Evidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from randomized controlled trials, we used a target trial emulation approach to compare arteriovenous fistula (AVF) versus arteriovenous graft (AVG) creation among elderly patients receiving HD. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Elderly patients included in the US Renal Data System who initiated HD with a catheter and had an AVF or AVG created within 6 months of starting HD. EXPOSURE: Creation of an AVF versus an AVG as the incident arteriovenous access. OUTCOMES: All-cause mortality, all-cause and cause-specific hospitalization, and sepsis. ANALYTICAL APPROACH: Target trial emulation approach, high-dimensional propensity score and inverse probability of treatment weighting, and instrumental variable analysis using the proclivity of the operating physician to create a fistula as the instrumental variable. RESULTS: A total of 19,867 patients were included, with 80.1% receiving an AVF and 19.9% an AVG. In unweighted analysis, AVF creation was associated with significantly lower risks of mortality and hospitalization, especially within 6 months after vascular access creation. In inverse probability of treatment weighting analysis, AVF creation was associated with lower incidences of mortality and hospitalization within 6 months after creation (hazard ratios of 0.82 [95% CI, 0.75-0.91] and 0.82 [95% CI, 0.78-0.87] for mortality and all-cause hospitalization, respectively), but not between 6 months and 3 years after access creation. No association between AVF creation and mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization was found in instrumental variable analyses. However, AVF creation was associated with a lower risk of access-related hospitalization not due to infection. LIMITATIONS: Potential for unmeasured confounding, analyses limited to elderly patients, and absence of data on actual access use during follow-up. CONCLUSIONS: Using observational data to emulate a target randomized controlled trial, the type of initial arteriovenous access created was not associated with the risks of mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization among elderly patients who initiated HD with a catheter.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lyu B, Chan MR, Yevzlin AS, et al. Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach. Am J Kidney Dis. 2021. PMID: 34118301. doi:10.1053/j.ajkd.2021.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。